Skip to main content
SpringerLink
Log in
Book cover

Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders pp 95–116Cite as

Prevention and Treatment of Transplant Rejection in Keratoplasty

  • Chapter
  • First Online:

  • 681 Accesses

Abstract

With more than 100.000 procedures a year, keratoplasty is the most frequent transplantation procedure in humans. Technical advances in microsurgery have moved forward to transplant isolated layers of the cornea. However, immune-mediated rejection remains a key problem. Continued preventive and therapeutic efforts are therefore required to improve the prognosis after keratoplasty.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   64.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol 1992;110:1392–403.

    Google Scholar 

  2. Allan BD, Terry MA, Price Jr FW, Price MO, Griffin NB, Claesson M. Corneal transplant rejection rate and severity after endothelial keratoplasty. Cornea. 2007;26(9):1039–42.

    PubMed  Google Scholar 

  3. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol. 1981;99:599–604.

    CAS  PubMed  Google Scholar 

  4. Al-Yousuf N, Mavrikakis I, Mavrikakis E, Daya SM. Penetrating keratoplasty: indications over a 10 year period. Br J Ophthalmol. 2004;88(8):998–1001.

    CAS  PubMed Central  PubMed  Google Scholar 

  5. Ardjomand N, Berghold A, Reich ME. Loss of corneal Langerhans cells during storage in organ culture medium, Optisol and McCarey-Kaufman medium. Eye. 1998;12:134–8.

    PubMed  Google Scholar 

  6. Arentsen JJ. Corneal transplant allograft reaction: possible predisposing factors. Trans Am Ophthalmol Soc. 1983;81:361–402.

    CAS  PubMed Central  PubMed  Google Scholar 

  7. Baggesen K, Lamm LU, Ehlers N. Significant effect of high-resolution HLA-DRB1 matching in high-risk corneal transplantation. Transplantation. 1996;62:1273–7.

    CAS  PubMed  Google Scholar 

  8. Bahar I, Kaiserman I, McAllum P, Slomovic A, Rootman D. Comparison of posterior lamellar keratoplasty techniques to penetrating keratoplasty. Ophthalmology. 2008;115(9):1525–33.

    PubMed  Google Scholar 

  9. Beckingsale P, Mavrikakis I, Al-Yousuf N, Mavrikakis E, Daya SM. Penetrating keratoplasty: outcomes from a corneal unit compared to national data. Br J Ophthalmol. 2006;90(6):728–31.

    CAS  PubMed Central  PubMed  Google Scholar 

  10. Bertelmann E, Reinhard T, Pleyer U. Current practice of immune prophylaxis and therapy in perforating keratoplasty. A survey of members of the Cornea Section of the German Ophthalmological Society. Ophthalmologe. 2003;100:1031–5.

    CAS  PubMed  Google Scholar 

  11. Beyer CF, Hill JM, Reidy JJ, et al. Corneal nerve disruption reactivates virus in rabbits latently infected with HSV-1. Invest Ophthalmol Vis Sci. 1990;31:925–32.

    CAS  PubMed  Google Scholar 

  12. Birnbaum F, Bohringer D, Sokolovska Y, Sundmacher R, Reinhard T. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study. Transplantation. 2005;79:964–8.

    CAS  PubMed  Google Scholar 

  13. Birnbaum F, Jehle T, Schwartzkopff J, Sokolovska Y, Böhringer D, Reis A, Reinhard T. Basiliximab following penetrating risk-keratoplasty-a prospective randomized pilot study. Klein Monbl Augenheilkd. 2008;225(1):62–5.

    CAS  Google Scholar 

  14. Birnbaum F, Mayweg S, Reis A, Böhringer D, Seitz B, Engelmann K, Messmer EM, Reinhard T. Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study. Eye (Lond). 2009;23(11):2063–70.

    CAS  Google Scholar 

  15. Birnbaum F, Reis A, Böhringer D, Skokolowska Y, Mayer K, Voiculescu A, Oellerich M, Sundmacher R, Reinhard T. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation. 2006;81(5):767–72 (EBM 1+, B).

    CAS  PubMed  Google Scholar 

  16. Bohringer D, Reinhard T, Bohringer S, Enczmann J, Godehard E, Sundmacher R. Predicting time on the waiting list for HLA matched corneal grafts. Tissue Antigens. 2002;59:407–11.

    CAS  PubMed  Google Scholar 

  17. Bohringer D, Reinhard T, Duquesnoy RJ, Bohringer S, Enczmann J, Lange P, Claas F, Sundmacher R. Beneficial effect of matching at the HLA-A and -B amino-acid triplet level on rejection-free clear graft survival in penetrating keratoplasty. Transplantation. 2004;77:417–21.

    PubMed  Google Scholar 

  18. Borderie VM, Kantelip BM, Genin PO, Masse M, Laroche L, Delbosc BY. Modulation of HLA-DR and CD1a expression on human cornea with low-dose UVB irradiation. Curr Eye Res. 1996;15:669–79.

    CAS  PubMed  Google Scholar 

  19. Bradley BA, Vail A, Gore SM, Rogers CA, Armitage WJ, Nicholls S, Easty DL. Negative effect of HLA-DR matching on corneal transplant rejection. Transplant Proc. 1995;27:1392–4.

    CAS  PubMed  Google Scholar 

  20. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol. 1993;13:4760–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  21. Casey TA, Gibbs D. Complications in corneal grafting. Trans Ophthalmol Soc UK. 1972;92:517–30.

    CAS  PubMed  Google Scholar 

  22. Chatel MA, Larkin DF. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol. 2010;150(2):179–84.

    CAS  PubMed  Google Scholar 

  23. Cobo LM, Coster DJ, Rice NS, Jones BR. Prognosis and management of corneal transplantation for herpetic keratitis. Arch Ophthalmol. 1980;98:1755–9.

    CAS  PubMed  Google Scholar 

  24. Cockerham GC, Bijwaard K, Sheng ZM, Hidayat AA, Font RL, McLean IW. Primary graft failure: a clinicopathologic and molecular analysis. Ophthalmology. 2000;107(11):2083–90; Discussion 2090–1.

    CAS  PubMed  Google Scholar 

  25. Costa DC, de Castro RS, Kara-Jose N. Case-control study of subconjunctival triamcinolone acetonide injection vs intravenous methylprednisolone pulse in the treatment of endothelial corneal allograft rejection. Eye (Lond). 2009;23(3):708–14.

    CAS  Google Scholar 

  26. Castro DC, Castro RS, Camargo MS, Kara-José N. Corneal allograft rejection: topical treatment vs. pulsed intravenous methylprednisolone - ten years’ result. Arq Bras Oftalmol. 2008;71(1):57–61.

    PubMed  Google Scholar 

  27. Dong Y, Huang YF, Wang LQ, Chen B. Experimental study on the effects of rapamycin in prevention of rat corneal allograft rejection. Zhonghua Yan Ke Za Zhi. 2005;41(10):930–5.

    PubMed  Google Scholar 

  28. Epstein RJ, Seedor JA, Dreizen NG, et al. Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. Ophthalmology. 1987;94(8):935–44.

    CAS  PubMed  Google Scholar 

  29. Ficker LA, Kirkness CM, Rice NS, Steele AD. The changing management and improved prognosis for corneal grafting in herpes simplex keratitis. Ophthalmology. 1989;96:1587–96.

    CAS  PubMed  Google Scholar 

  30. Garcia DD, Farjo Q, Musch DC, et al. Effect of prophylactic oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Cornea. 2007;26(8):930–4.

    PubMed  Google Scholar 

  31. Gore SM, Vail A, Bradley BA, Rogers CA, Easty DL, Armitage WJ. HLA-DR matching in corneal transplantation. Systematic review of published evidence. Corneal Transplant Follow-up Study Collaborators. Transplantation. 1995;60:1033–9.

    CAS  PubMed  Google Scholar 

  32. Guilbert E, Bullet J, Sandali O, Basli E, Laroche L, Borderie VM. Long-term rejection incidence and reversibility after penetrating and lamellar keratoplasty. Am J Ophthalmol. 2013;155:560–9.

    PubMed  Google Scholar 

  33. Haskova Z, Sproule TJ, Roopenian DC, Ksander AB. An immunodominant minor histocompatibility alloantigen that initiates corneal allograft rejection. Transplantation. 2003;75:1368–74.

    CAS  PubMed  Google Scholar 

  34. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy. Ophthalmology. 1994;101:128–33.

    CAS  PubMed  Google Scholar 

  35. Hill JC. Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye. 1995;9:422–8.

    PubMed  Google Scholar 

  36. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology. 1991;98:329–33.

    CAS  PubMed  Google Scholar 

  37. Hopkins KA, Maguire MG, Fink NE, Bias WB. Reproducibility of HLA-A, B, and DR typing using peripheral blood samples: results of retyping in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Group (corrected). Hum Immunol. 1992;33:122–8.

    CAS  PubMed  Google Scholar 

  38. Hudde T, Minassian DC, Larkin DF. Randomised controlled trial of corticosteroid regimens in endothelial corneal allograft rejection. Br J Ophthalmol. 1999;83:1348–52.

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Inoue K, Amano S, Kimura C, Sato T, Fujita N, Kagaya F, Kaji Y, Oshika T, Tsuru T, Araie M. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol. 2000;44:302–5.

    CAS  PubMed  Google Scholar 

  40. Inoue K, Kimura C, Amano S, Sato T, Fujita N, Kagaya F, Kaji Y, Tsuru T, Araie M. Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol. 2001;45:378–82.

    CAS  PubMed  Google Scholar 

  41. Javadi MA, Feizi S, Karbasian A, Rastegarpour A. Efficacy of topical ciclosporin A for treatment and prevention of graft rejection in corneal grafts with previous rejection episodes. Br J Ophthalmol. 2010;94(11):1464–7.

    CAS  PubMed  Google Scholar 

  42. Jiang W, Sun HM, Li XR, Yuan XB, Wang YQ, Zhang SX, Tian EJ, Yuan JQ. Combined rapamycin eye drop in nanometer vector and poly (lactic acid) wafers of cyclosporine A effectively prevents high-risk corneal allograft rejection in rabbits. Zhonghua Yan Ke Za Zhi. 2009;45(6):550–5.

    CAS  PubMed  Google Scholar 

  43. Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res. 2006;25(4):355–80.

    PubMed  Google Scholar 

  44. Kaye SB, Baker K, Bonshek R, Maseruka H, Grinfeld E, Tullo A, Easty DL, Hart CA. Human herpes viruses in the cornea. Br J Ophthalmol. 2000;84:563–71.

    CAS  PubMed Central  PubMed  Google Scholar 

  45. Kersten A, Sundmacher R, Reinhard T. Postoperative complications of penetrating keratoplasty in herpes infected eyes. Differential diagnosis, therapy and prognostic significance. Ophthalmologe. 1997;94(12):889–96.

    CAS  PubMed  Google Scholar 

  46. Khaireddin R, Wachtlin J, Hopfenmuller W, Hoffmann F. HLA-A, HLA-B and HLA-DR matching reduces the rate of corneal allograft rejection. Graefes Arch Clin Exp Ophthalmol. 2003;241:1020–8.

    CAS  PubMed  Google Scholar 

  47. Koay PY, Lee WH, Figueiredo FC. Opinions on risk factors and management of corneal graft rejection in the United Kingdom. Cornea. 2005;24:292–6.

    PubMed  Google Scholar 

  48. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–18.

    CAS  PubMed  Google Scholar 

  49. Lee SS, Kim H, Wang NS, Bungay PM, Gilger BC, Yuan P, Kim J, Csaky KG, Robinson MR. A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. Invest Ophthalmol Vis Sci. 2007;48(5):2023–9.

    PubMed  Google Scholar 

  50. Leibowitz HM, Kupferman A. Kinetics of topically administered prednisolone acetate. Optimal concentration for treatment of inflammatory keratitis. Arch Ophthalmol. 1976;94:1387–9.

    CAS  PubMed  Google Scholar 

  51. Mackay IR, Bignell JL, Smith PH, Crawford BA. Prevention of corneal-graft failure with the immunosuppressive drug azathioprine. Lancet. 1967;2:479–82.

    CAS  PubMed  Google Scholar 

  52. Maris Jr PJ, Correnti AJ, Donnenfeld ED. Intracameral triamcinolone acetonide as treatment for endothelial allograft rejection after penetrating keratoplasty. Cornea. 2008;27(7):847–50.

    PubMed  Google Scholar 

  53. Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol. 2003;241:1051–4.

    CAS  PubMed  Google Scholar 

  54. Mayweg S, Reinhard T, Spelsberg H, Reis A, Godehardt E, Sundmacher R. Ranking of systemic steroids after normal-risk keratoplasty. Results of a randomized prospective study. Ophthalmologe. 2005;102:497–501.

    CAS  PubMed  Google Scholar 

  55. Milani JK, Pleyer U, Dukes A, Chou HJ, Lutz S, Ruckert D, Schmidt KH, Mondino BJ. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology. 1993;100:890–6.

    CAS  PubMed  Google Scholar 

  56. Miller K, Huber C, Niederwieser D, Gottinger W. Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine. Transplantation. 1988;45:651–3.

    CAS  PubMed  Google Scholar 

  57. Munkhbat B, Hagihara M, Sato T, Tsuchida F, Sato K, Shimazaki J, Tsubota K, Tsuji K. Association between HLA-DPB1 matching and 1-year rejection-free graft survival in high-risk corneal transplantation. Transplantation. 1997;63:1011–6.

    CAS  PubMed  Google Scholar 

  58. Nicholls SM, Shimeld C, Easty DL, Hill TJ. Recurrent herpes simplex after corneal transplantation in rats. Invest Ophthalmol Vis Sci. 1996;37:425–35.

    CAS  PubMed  Google Scholar 

  59. Nyugen NX, Seitz B, Martus P, Langenbucher A, Cursiefen C. Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol. 2007;144(2):318–9.

    Google Scholar 

  60. Patel SV, Hodge DO, Bourne WM. Corneal endothelium and postoperative outcomes 15 years after penetrating keratoplasty. Trans Am Ophthalmol Soc. 2004;102:57–65.

    PubMed Central  PubMed  Google Scholar 

  61. Pepose JS, Gardner KM, Nestor MS, Foos RY, Pettit TH. Detection of HLA class I and II antigens in rejected human corneal allografts. Ophthalmology. 1985;92:1480–4.

    CAS  PubMed  Google Scholar 

  62. Perry HD, Donnenfeld ED, Acheampong A, Kanellopoulos AJ, Sforza PD, D’Aversa G, Wallerstein A, Stern M. Topical Cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5 % cyclosporine A into the cornea and anterior chamber. CLAO J. 1998;24:159–65.

    CAS  PubMed  Google Scholar 

  63. Pleyer U, Lutz S, Jusko WJ, Nguyen KD, Narawane M, Ruckert D, Mondino BJ, Lee VH, Nguyen K. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci. 1993;34:2737–42.

    CAS  PubMed  Google Scholar 

  64. Pleyer U, Raphael B, Kosmidis P, Ryffel B, Thiel HJ. Verteilung von Cyclophilin in okularen Geweben. Ophthalmologe. 1993;90:118.

    Google Scholar 

  65. Pleyer U, Schlickeiser S. The taming of the shrew? The immunology of corneal transplantation. Acta Ophthalmol. 2009;87(5):488–97.

    CAS  PubMed  Google Scholar 

  66. Pleyer U, Steuhl KP, Weidle EG, Lisch W, Thiel HJ. Corneal graft rejection: incidence, manifestation, and interaction of clinical subtypes. Transplant Proc. 1992;24:2034–7.

    CAS  PubMed  Google Scholar 

  67. Pleyer U, Weidle EG, Lisch W, Steuhl KP, Möhrle C, Richter U, Zierhut M, Selbmann HK. Clinical types of immunologic transplant reactions following perforating keratoplasty. Fortschr Ophthalmol. 1990;87(1):14–9.

    CAS  PubMed  Google Scholar 

  68. Pleyer U, Yang J, Knapp S, Schacke H, Schmees N, Orlic N, Otasevic L, De Ruijter M, Ritter T, Keipert S. Effects of a selective glucocorticoid receptor agonist on experimental keratoplasty. Graefes Arch Clin Exp Ophthalmol. 2005;243:450–5.

    CAS  PubMed  Google Scholar 

  69. Poon AC, Forbes JE, Dart JK, Subramaniam S, Bunce C, Madison P, Ficker LA, Tuft SJ, Gartry DS, Buckley RJ. Systemic cyclosporin A in high-risk penetrating keratoplasties: a case-control study. Br J Ophthalmol. 2001;85:1464–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Poon A, Constantinou M, Lamoureux E, Taylor HR. Topical Cyclosporin A in the treatment of acute graft rejection: a randomized controlled trial. Clin Experiment Ophthalmol. 2008;36(5):415–21.

    PubMed  Google Scholar 

  71. Randleman JB, Stulting D. Prevention and treatment of corneal graft rejection: current practice patterns. Cornea. 2006;25:286–90.

    PubMed  Google Scholar 

  72. Refojo D, Liberman AC, Holsboer F, Arzt E. Transcription factor-mediated molecular mechanisms involved in the functional cross-talk between cytokines and glucocorticoids. Immunol Cell Biol. 2001;79:385–94.

    CAS  PubMed  Google Scholar 

  73. Reinhard T, Hutmacher M, Sundmacher R. Acute and chronic immune reactions after penetrating keratoplasty with normal immune risk. Klin Monatsbl Augenheilkd. 1997;210:139–43.

    CAS  PubMed  Google Scholar 

  74. Reinhard T, Mayweg S, Reis A, Sundmacher R. Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. Transpl Int. 2005;18:193–7.

    CAS  PubMed  Google Scholar 

  75. Reinhard T, Reis A, Bohringer D, Malinowski M, Voiculescu A, Heering P, Godehardt E, Sunmacher R. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years’ results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol. 2001;239:367–72.

    CAS  PubMed  Google Scholar 

  76. Reinhart WJ, Musch DC, Jacobs DS, Lee WB, Kaufman SC, Shtein RM. Deep anterior lamellar keratoplasty as an alternative to penetrating keratoplasty a report by the american academy of ophthalmology. Ophthalmology. 2011;118(1):209–18.

    PubMed  Google Scholar 

  77. Reis A, Mayweg S, Birnbaum F, Reinhard T. Long-term results of FK 506 eye drops following corneal transplantation. Klin Monbl Augenheilkd. 2008;225(1):57–61.

    CAS  PubMed  Google Scholar 

  78. Reisr A, Reinhard T, Voiculescu A, et al. Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease. Klin Monbl Augenheilkd. 2001;218(3):183–6.

    CAS  PubMed  Google Scholar 

  79. Remeijer L, Doornenbal P, Geerards AJ, Rijneveld WA, Beekhuis WH. Newly acquired herpes simplex virus keratitis after penetrating keratoplasty. Ophthalmology. 1997;104:648–52.

    CAS  PubMed  Google Scholar 

  80. Remeijer L, Maertzdorf J, Buitenwerf J, Osterhaus AD, Verjans GM. Corneal herpes simplex virus type 1 superinfection in patients with recrudescent herpetic keratitis. Invest Ophthalmol Vis Sci. 2002;43:358–63.

    PubMed  Google Scholar 

  81. Rezende RA, Bisol T, Hammersmith K, Hofling-Lima AL, Webster GF, Freitas JF, Rapuano CJ, Laibson PR, Cohen EJ. Epithelial herpetic simplex keratitis recurrence and graft survival after corneal transplantation in patients with and without atopy. Am J Ophthalmol. 2007;143(4):623–8.

    PubMed  Google Scholar 

  82. Rezende RA, Uchoa UB, Raber IM, Rapuano CJ, Laibson PR, Cohen EJ. New onset of herpes simplex virus epithelial keratitis after penetrating keratoplasty. Am J Ophthalmol. 2004;137(3):415–9.

    PubMed  Google Scholar 

  83. Rinne JR, Stulting RD. Current practices in the prevention and treatment of corneal graft rejection. Cornea. 1992;11:326–8.

    CAS  PubMed  Google Scholar 

  84. Ritter T, Pleyer U. Novel gene therapeutic strategies for the induction for the induction of tolerance in cornea transplantation. Expert Rev Clin Immunol. 2009;5(6):749–64.

    CAS  PubMed  Google Scholar 

  85. Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U. Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol. 2002;86:988–92.

    CAS  PubMed Central  PubMed  Google Scholar 

  86. Sanfilippo F, MacQueen JM, Vaughn WK, Foulks GN. Reduced graft rejection with good HLA-A and B matching in high-risk corneal transplantation. N Engl J Med. 1986;315:29–35.

    CAS  PubMed  Google Scholar 

  87. Sano Y, Ksander BR, Streilein JW. Minor H, rather than MHC, alloantigens offer the greater barrier to successful orthotopic corneal transplantation in mice. Transpl Immunol. 1996;4:53–6.

    CAS  PubMed  Google Scholar 

  88. Schmitz K, Hitzer S, Behrens-Baumann W. Immune suppression by combination therapy with basiliximab and cyclosporin in high-risk keratoplasty. A pilot study. Ophthalmologe. 2002;99:38–45.

    CAS  PubMed  Google Scholar 

  89. Seitz B, Langenbucher A, Diamantis A, Cursiefen C, Küchle M, Naumann GO. Immunological graft reactions after penetrating keratoplasty - a prospective randomized trial comparing corneal excimer laser and motor trephination. Klin Monbl Augenheilkd. 2001;218(11):710–9.

    CAS  PubMed  Google Scholar 

  90. Severin M. Immune reactions following keratoplasty. Klin Monatsbl Augenheilkd. 1986;188:200–8.

    CAS  PubMed  Google Scholar 

  91. Shapiro R, Fung JJ, Jain AB, Parks P, Todo S, Starzl TE. The side effects of FK 506 in humans. Transplant Proc. 1990;22:35–6.

    CAS  PubMed Central  PubMed  Google Scholar 

  92. Sherif Z, Pleyer U. Corticosteroids in ophthalmology: past-present-future. Ophthalmologica. 2002;216:305–15.

    PubMed  Google Scholar 

  93. Shi W, Gao H, Xie L, Wang S. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci. 2006;47(8):3339–44.

    PubMed  Google Scholar 

  94. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol. 1992;10:519–60.

    CAS  PubMed  Google Scholar 

  95. Shi W, Chen M, Xie L, Liu M, Gao H, Wang T, Wu X, Zhao J. A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study. Ophthalmology. 2013;120:695–702.

    PubMed  Google Scholar 

  96. Shimazaki J, Den S, Omoto M, Satake Y, Shimmura S, Tsubota K. Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol. 2011;152:33–9.

    CAS  PubMed  Google Scholar 

  97. Sinha R, Jhanji V, Verma K, Sharma N, Biswas NR, Vajpayee RB. Efficacy of topical cyclosporine A 2 % in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol. 2010;248(8):1167–72.

    CAS  PubMed  Google Scholar 

  98. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. 2001;108:1838–44.

    CAS  PubMed  Google Scholar 

  99. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice–evidence that the immunogenetic rules of rejection do not apply. Transplantation. 1992;54:694–704.

    CAS  PubMed  Google Scholar 

  100. Stanojlovic S, Schlickeiser S, Appelt C, Vogt K, Schmitt-Knosalla I, Haase S, Ritter T, Sawitzki B, Pleyer U. Influence of combined treatment of low dose rapamycin and cyclosporin A on corneal allograft survival. Graefes Arch Clin Exp Ophthalmol. 2010;248(10):1447–56.

    CAS  PubMed  Google Scholar 

  101. Sugar A, Bokosky JE, Meyer RF. A randomized trial of topical corticosteroids in epithelial healing after keratoplasty. Cornea. 1984;3:268–71.

    PubMed  Google Scholar 

  102. Sundmacher R, Reinhard T, Heering P. Six years’ experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. A retrospective study. Ger J Ophthalmol. 1992;1:432–6.

    CAS  PubMed  Google Scholar 

  103. Takahashi N, Hayano T, Suzuki M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature. 1989;337:473–5.

    CAS  PubMed  Google Scholar 

  104. Tambasco FP, Cohen EJ, Nguyen LH, Rapuano CJ, Laibson PR. Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. Arch Ophthalmol. 1999;117(4):445–9.

    CAS  PubMed  Google Scholar 

  105. Tan DT, Janardhanan P, Zhou H, Chan YH, Htoon HM, Ang LP, Lim LS. Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study. Ophthalmology. 2008;115(6):975–82.

    PubMed  Google Scholar 

  106. Tandon R, Verma K, Chawla B, Sharma N, Tiliyal JS, Kalaivani M, Vajpayee RB. Intravenous dexamethasone vs methylprednisolone pulse therapy in the treatment of acute endothelial graft rejection. Eye (Lond). 2009;23(3):635–9.

    CAS  Google Scholar 

  107. Thiel MA, Ross CA, Coster DJ. Corneal allograft rejection: has the time come for intravenous pulsed methylprednisolone? A debate. Clin Experiment Ophthalmol. 2000;28:398–404.

    CAS  PubMed  Google Scholar 

  108. Unal M, Yücel I. Evaluation of topical ciclosporin 0.05 % for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol. 2008;92(10):1411–4.

    CAS  PubMed  Google Scholar 

  109. van Rooij J, Rijneveld WJ, Remeijer L, Völker-Dieben HJ, Eggink CA, Geerards AJ, Mulder PG, Doornenbal P, Beekhuis WH. Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo-controlled multicenter trial. Ophthalmology. 2003;110(10):1916–9.

    PubMed  Google Scholar 

  110. Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitage WJ. Influence of donor and histocompatibility factors on corneal graft outcome. Transplantation. 1994;58:1210–6.

    CAS  PubMed  Google Scholar 

  111. Varssano D, Russ V, Linhart Y, Lazar M. Air transportation of corneal tissue: experience with local compared to transatlantic donor corneas. Cornea. 2005;24:674–7.

    PubMed  Google Scholar 

  112. Volker-Dieben HJ, Claas FH, Schreuder GM, Schipper RF, Pels E, Persijn GG, Smits J, D’Amaro J. Beneficial effect of HLA-DR matching on the survival of corneal allografts. Transplantation. 2000;70:640–8.

    CAS  PubMed  Google Scholar 

  113. Völker-Dieben HJ, Kok-van Alphen CC, Kruit PJ. Advances and disappointments, indications and restrictions regarding HLA-matched corneal grafts in high-risk cases. Doc Ophthalmol. 1979;46:219–26.

    PubMed  Google Scholar 

  114. Williams KA, Lowe M, Bartlett C, Kelly TL, Coster DJ. Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation. 2008;86(12):1720–4.

    PubMed  Google Scholar 

  115. Williams KA, Muehlberg SM, Lewis RF, Coster DJ. Influence of advanced recipient and donor age on the outcome of corneal transplantation. Australian Corneal Graft Registry. Br J Ophthalmol. 1997;81:835–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  116. Yalcindag FN, Incel O, Ozdemir O. Effectiveness of tacrolimus in high-risk limbal allo-graft transplantation. Ann Ophthalmol (Skokie). 2008;40(3–4):152–6.

    Google Scholar 

  117. You IC, Yoon KC. Therapeutic effect of intravitreal injection of triamcinolone in the treatment of endothelial graft rejection: a pilot study. Cornea. 2012;31(10):1135–40.

    PubMed  Google Scholar 

  118. Young AL, Rao SK, Cheng LL, Wong AK, Leung AT, Lam DS. Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Eye (Lond). 2002;16(3):304–8.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Charité, Augustenburger Platz 1, Berlin, 13353, Germany

    Uwe Pleyer MD

  2. Department of Opthalmology, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, 13353, Germany

    Anna-Karina Brigitte Maier MD

Authors
  1. Uwe Pleyer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna-Karina Brigitte Maier MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uwe Pleyer MD .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, Charité Campus Virchow-Klinikum, Berlin, Germany

    Uwe Pleyer

  2. Division of Ophthalmology, Miguel Hernandez University, Vissum-Instituto Oftalmologico de Alicante, Alicante, Spain

    Jorge L. Alió

  3. Centre of Ocular Inflammation and Infection OCUVAC, Medical University of Vienna Laura Bassi Centre of Expertise, Vienna, Austria

    Talin Barisani-Asenbauer

  4. Department of Ophthalmology, Pitié-Salpêtrière’s University Hospital, Paris, France

    Phuc Le Hoang

  5. Doheny Eye Institute, University of Southern California Keck School of Medicine, Los Angeles, California, USA

    Narsing A. Rao

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pleyer, U., Maier, AK.B. (2014). Prevention and Treatment of Transplant Rejection in Keratoplasty. In: Pleyer, U., Alió, J., Barisani-Asenbauer, T., Le Hoang, P., Rao, N. (eds) Immune Modulation and Anti-Inflammatory Therapy in Ocular Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54350-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54350-0_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54349-4

  • Online ISBN: 978-3-642-54350-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation